13F Insight
DOSSIER · 13F-HR · Q1 2026

SUVRETTA CAPITAL MANAGEMENT, LLC

$3.9B in tracked AUM across 89 positions as of Q1 2026.

SC
CIK 0001569064 · last filed Mar 31, 2026
Total AUM
$3.9B
as of Q1 2026
Holdings
89
—
positions
Whale Score
61
61
tracked
Activity
—
no data
changes this Q
AI Analysis · Q1 2026
Comprehensive Analysis of SUVRETTA CAPITAL MANAGEMENT 13F Filing
1. Portfolio Overview

Suvretta Capital Management reported a significant portfolio contraction for the period ending September 30, 2025. The total portfolio value decreased by 18.0%, dropping from $3.32 billion to $2.72 billion. This reduction in assets under management (AUM) coincides with a substantial shift in strategy, evidenced by high portfolio turnover. The fund executed 21 new buys and 21 complete exits, indicating a...

2. Key Holdings

The portfolio is anchored by a massive position in the SPDR S&P 500 ETF Trust (SPY), which accounts for 19.60% of the total value ($532.94M). This is the firm's largest position by a wide margin and was increased by 14.3% during the quarter, signaling a desire to maintain significant exposure to the broader U.S. equity market despite the rotation in individual names.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q1 2026. Methodology

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$290M12.3M7.4%02
MANE
VERADERMICS INC
$263M4.2M6.7%03
SPY
STATE STR SPDR S&P 500 ETF T
$228M350K5.8%04
PVLA
PALVELLA THERAPEUTICS INC NE
$144M1.2M3.7%05
APLS
APELLIS PHARMACEUTICALS INC
$142M3.5M3.6%06
LEGN
LEGEND BIOTECH CORP
$137M7.6M3.5%07
BNTC
BENITEC BIOPHARMA INC
$123M11.5M3.1%08
CAPR
CAPRICOR THERAPEUTICS INC
$116M3.8M3.0%09
N44445109
IMMATICS N.V
$110M11.2M2.8%10
RCUS
ARCUS BIOSCIENCES INC
$109M5.0M2.8%

Filing history

2026Q1Mar 31
$3.9B▼ 19.8%
89 positionsView →2025Q4Dec 31
$4.9B▲ 79.5%
93 positionsView →2025Q3Sep 30
$2.7B▼ 18.0%
59 positionsView →2025Q2Jun 30
$3.3B▲ 23.1%
98 positionsLocked2025Q1Mar 31
$2.7B▼ 8.2%
100 positionsLocked2024Q4Dec 31
$2.9B▼ 6.1%
96 positionsLocked2024Q3Sep 30
$3.1B▲ 14.8%
98 positionsLocked2024Q2Jun 30
$2.7B▲ 1.1%
98 positionsLocked2024Q1Mar 31
$2.7B▲ 21.7%
101 positionsLocked2023Q4Dec 31
$2.2B▲ 19.5%
88 positionsLocked2023Q3Sep 30
$1.9B▼ 1.1%
87 positionsLocked2023Q2Jun 30
$1.9B▼ 21.0%
100 positionsLocked
Showing 12 of 48